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The loudness dependence of auditory evoked poten-
tials (LDAEPs) has been proposed as a non-invasive
biological marker of in vivo central serotonergic
function (Hegerl and Juckel, 1993). It is a measure
of auditory cortex activity, reflecting an increase or
decrease in the slope of auditory evoked potentials with
increasing tone loudness (Hegerl and Juckel, 1993). It
has been postulated that the excitability of the auditory
cortex is under serotonergic control, such that an
increase or decrease in serotonin function is associated
with reduced or increased cortical excitability (e.g.
decrease and increase in the slope of the LDAEP,
respectively).* Correspondence to: P. J. Nathan, Brain Mapping Unit, Department of
Psychiatry, University of Cambridge, Addenbrooke’s Hospital, Hills Road,
Cambridge CB2 2QQ, UK. Tel: þ44 (0) 1223 296000, Fax: þ44 (0) 1223
296002. E-mail: pn254@cam.ac.uk
Copyright # 2010 John Wiley & Sons, Ltd.The majority of evidence in support of an association
between serotonin function and the LDAEP has been
based on pharmacological studies in animals (Juckel
et al., 1997, 1999), with additional indirect evidence
from clinical disorders with a presumed serotonergic
dysfunction including migraine (Wang et al., 1999),
borderline personality disorder (Norra et al., 2003),
generalised anxiety disorder (Senkowski et al., 2003)
and schizophrenia (Juckel et al., 2003). However,
human studies that have directly examined the effects
of serotonergic modulation on the LDAEP have been
unable to support the animal studies (Juckel et al.,
1997, 1999). In one human study, we showed that the
slope of the LDAEP was reduced by acutely enhancing
synaptic serotonin with the selective serotonin re-
uptake inhibitor (SSRI) citalopram (Nathan et al.,
2006). However, subsequent studies, including our
own, have shown insensitivity of the LDAEP to
enhancement of serotonin neurotransmission following
acute administration of the SSRI’s citalopram (GuilleReceived 19 February 2010
Accepted 18 May 2010
424 j. oliva ET AL.et al., 2008; Uhl et al., 2006), escitalopram or sertraline
(Guille et al., 2008). Similarly, depletion of serotonin
with depletion of the serotonin precursor, tryptophan
was also found to have no effect on the LDAEP in the
majority of studies (Dierks et al., 1999; Norra et al.,
2008; O’Neill et al., 2008a) while one study reported
a paradoxical decrease in the LDAEP (Kähkönen et al.,
2002). Overall these findings suggest that the LDAEP
may be insensitive to acute changes in serotonin
neurotransmission (O’Neill et al., 2008b).
Relatively little is known about the impact of other
neurotransmitter systems on the LDAEP. A greater
understanding of the sensitivity of the LDAEP to
multiple neurotransmitter systems is required because
of the reported changes in the LDAEP in clinical
disorders (Juckel et al., 2003; Norra et al., 2003;
Senkowski et al., 2003; Wang et al., 1999) and the
lack of knowledge about the underlying influence of
neurochemicals other than serotonin. We have recently
shown that the LDAEP is sensitive to NMDA receptor
modulation (O’Neill et al., 2007) but insensitive to
dopamine D1 and D2 receptor stimulation (O’Neill
et al., 2006) and dopamine depletion (O’Neill et al.,
2008a). It is yet to be established whether the LDAEP
is directly modulated by changes in noradrenergic neu-
rotransmission in healthy subjects, although it has been
recently demonstrated that the LDAEP at baseline may
be a predictor of treatment response to noradrenergic
antidepressants in a clinical sample of patients with
depression (Juckel et al., 2007; Linka et al., 2009).
Hence, the current study examined the acute effects
of noradrenergic modulation using the noradrenaline
reuptake inhibitor, reboxetine, on the LDAEP in heal-
thy subjects. Due to inconsistent reports with SSRIs,
we also further examined the effects of the SSRI
citalopram, on the LDAEP.
METHODS
Participants
The sample consisted of 21 healthy, drug naive,
participants aged 18–32 (mean age 22.05, SD 3.44) with
no current or past history of psychiatric or neurological
disorders confirmed by a semi-structured medical exami-
nation by a registered physician. All participants provided
written informed consent to take part in the study, which
was approved by both the Swinburne and Monash
University Human Research Ethics Committees.
Design
The study utilised a double-blind, placebo-controlled
within-subject design. Participants were tested underCopyright # 2010 John Wiley & Sons, Ltd.three acute treatment conditions: citalopram (Cipramil,
20 mg), reboxetine (Edronax, 4 mg) and placebo. Order
of assignment to treatment groups was randomised
and counterbalanced, separated by a minimum 7-day
washout period. Females were tested during the folli-
cular phase of their menstrual cycle.
Procedure
The study was conducted at the Brain Sciences Institute.
On the day of testing, participants were administered
citalopram, reboxetine or placebo at approximately
10 am. Event-related potential recordings were per-
formed 2 h post-treatment to coincide with peak phar-
macokinetic effects of both reboxetine (2 h; Dostert
et al., 1997) and citalopram (2–4 h; Hyttel, 1994) and
pharmacodynamic effects of citalopram (Kemp et al.,
2004).
Data acquisition
Electroencephalographic (EEG) data were recorded
as described in our previous studies (Nathan et al.,
2006; O’Neill et al., 2006, 2007). This included EEG
recording using tin electrodes from 61 scalp sites
according to the international 10/20 system using a
Quickcap as well as 9 mm diameter tin electrodes
attached at the mastoids for re-referencing, and below
the left eye for recording eye movement. Auditory
stimuli of the loudness dependency paradigm consisted
of fifty 1000 Hz tones (1000 Hz, 100 ms duration inc-
luding 10 ms rise and 10 ms fall time, SOA randomised
between 1600 and 2100 ms) at a range of intensities
(60, 70, 80, 90 and 100 dB), presented binaurally in a
pseudorandom order through single-use foam EAR
inserts. Participants were also presented with a series
of faces and asked to respond with a button press if
the face had a nose. The purpose of this visual task was
to distract attention away from the auditory stimuli
as attention has been shown to modulate the LDAEP
in humans (Baribeau and Laurent, 1987). Data were
collected with a sampling rate of 500 Hz and a band-
pass filter of 0.5–100 Hz. The data were recorded using
NeuroScan software with SynAmps2TM amplifiers
(NeuroScan).
Data analysis
Electroencephalogram data were digitally re-refer-
enced to the average recorded from the mastoid
electrodes, low-pass filtered at 30 Hz (24 dB/oct) and
epoched 100–400 ms post-auditory stimulus. Ocular
artefact was corrected using the Croft and Barry (2000)Hum. Psychopharmacol Clin Exp 2010; 25: 423–427.
DOI: 10.1002/hup
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were rejected and averages then created for each of the
five intensities separately. Averages were created for
each of the five intensities separately with a mean of
47.8 2.2 sweeps per intensity. On the grand mean
waveform, the N1 and P2 peaks were identified at 100
and 185 ms respectively at the Cz electrode. The N1
and P2 peaks were then detected from the session mean
waveforms of each participant at 70–130 and 110–
260 ms respectively. The latencies of the session mean
peaks were then used to determine the peak detection
time ranges for each intensity waveform of that session
(N1:15 ms; P2:30 ms). The peaks were determined
automatically at the Cz electrode and subsequently
visually inspected by the investigator to ensure accu-
racy. N1/P2 amplitude was calculated as the differ-
ences in amplitude between P2 and N1. The slope of
the N1/P2 was calculated as the least squares linear
regression slope, with stimulus intensity the indepen-
dent variable and N1/P2 amplitude the dependent
variable.Figure 1. Grand mean auditory evoked potentials at Cz for placebo,
citalopram and reboxetine treatment conditions at 60, 80 and 100 dB
intensities of the auditory stimuliStatistical analysis
A repeated measures linear contrast was performed to
determine whether N1/P2 amplitude increased linearly
with stimulus intensity in the placebo condition, and
two repeated measures planned contrasts were perfor-
med to test for an effect of citalopram and reboxetine
(compared to placebo) on the slope of the LDAEP.
Gender was employed as a between-subjects factor
to reduce error variance as gender has been found to
influence visual amplitude–intensity slopes (Buchs-
baum and Pfefferbaum, 1971; Camposano and Lolas,
1992). Because these two comparisons were based on a
theoretically driven rationale and because there are
fewer tests than degrees of freedom, each planned
contrast had an alpha level set at 0.05 (Tabachnick and
Fidell, 2007).RESULTS
Four people were excluded from the analysis because
recognisable ERP components (and in particular the
N1/P2 complex) could not be discerned in the wave-
forms. The remaining samples [n¼ 17 (M¼ 8, F¼ 9)]
are presented here. The N1/P2 amplitude increased
linearly with increasing stimulus intensity in the pla-
cebo condition (F(1, 16)¼ 42.67, p< 0.0001, partial
h2¼ 0.73) (Figure 1).
The mean slopes for placebo, citalopram and rebo-
xetine were 0.33, 0.38 and 0.30 respectively (Figure 2).Copyright # 2010 John Wiley & Sons, Ltd.Compared to placebo, there was no significant effect of
citalopram (F(1,15)¼ 0.09, p> 0.05, partial h2¼ 0.006)
or reboxetine (F(1, 15)¼ 3.92, p> 0.05, partial h2¼
0.207) on the LDAEP slope (Figure 2).DISCUSSION
Acutely enhancing serotonergic or noradrenergic neu-
rotransmission with citalopram and reboxetine respect-
ively did not modulate the LDAEP. These findings are
consistent with the majority of studies conducted in
humans that have similarly shown that acute enhance-
ment of synaptic serotonin with the SSRI’s citalopram
(Guille et al., 2008; Uhl et al., 2006), escitalopram and
sertraline (Guille et al., 2008) and depletion of synapticHum. Psychopharmacol Clin Exp 2010; 25: 423–427.
DOI: 10.1002/hup
Figure 2. (a) Mean N1/P2 amplitude (mV) plotted against stimulus intensity (loudness, dB) and (b) mean values (mean standard deviation) of LDAEP
(mV/10 dB) at Cz, for placebo, citalopram and reboxetine treatment conditions
426 j. oliva ET AL.serotonin using tryptophan depletion (O’Neill et al.,
2008a) has no effect on the LDAEP. The insensitivity
of the LDAEP to noradrenergic modulation supports
previous studies in animals and humans. For example,
the a2-receptor agonist clonidine was found to have
had no effect on the LDAEP in cats (Juckel et al.,
1997), and in humans, a lack of association was rep-
orted between the noradrenaline metabolite, 3-meth-
oxy-4-hydroxyphenylglycol (MHPG), in CSF and the
amplitude–intensity function of visual evoked poten-
tials (Von Knorring and Perris, 1981).
Based on these studies it could be argued that the
LDAEP is insensitive to acute changes in serotonergic
or noradrenergic neurotransmission and hence the
LDAEP may be considered a poor pharmacodynamic
marker of these neurochemical systems. Although it is
possible that the LDAEP may be sensitive to long-term
changes in serotonergic function (for a review see
O’Neill et al., 2008b) and thus may potentially be a
trait or biological marker, this is yet to be directly
demonstrated. Together, the findings suggest that the
changes in the LDAEP previously reported in clinical
disorders (Juckel et al., 2003; Norra et al., 2003;
Senkowski et al., 2003; Wang et al., 1999) may not be
entirely attributed to a dysfunction in the serotonergic
system as there is insufficient consistent data linking
changes in serotonergic neurotransmission and the
LDAEP and such a relationship is yet to be directly
shown following long-term modulation of the serot-
onin neurotransmission. As we have previously shown
that the LDAEP is sensitive to NMDA receptor
modulation (O’Neill et al., 2007), it is possible that
the LDAEP changes observed in clinical disorders
including schizophrenia and mood disorders may be
secondary to glutamatergic dysfunction (Laruelle et al.,
2003; Sanacora et al., 2008). Future studies focussing on
the effects of long-term modulation of the serotoni-Copyright # 2010 John Wiley & Sons, Ltd.nergic (and other systems) on the LDAEP will help
clarify the neurochemical basis of the LDAEP changes
observed in clinical disorders.
There are some methodological issues that warrant
discussion. First, the negative findings are unlikely due
to inadequate power as a statistical analysis showed
that the effect sizes were small and greater than 200
subjects would be required to achieve significant
effects (with a power of 0.8 at alpha 0.05). Second, this
study used scalp data to determine the slope of the
LDAEP. Previous studies have claimed that the dipole
source localisation method is more sensitive than the
scalp-derived method (Hegerl et al., 1994; Hegerl and
Juckel, 1993) as it can separate the tangential dipole
which may be more sensitive to changes in serotonin
neurotransmission (Campbell et al., 1987). However,
as yet, the advantage of dipole source localisation
method over the scalp-derived method has not been
directly demonstrated. Furthermore, we recently sho-
wed that the dipole source analysis is no more sensitive
than the scalp-derived method in detecting the acute
effects of citalopram on the LDAEP (Guille et al.,
2008). As such, it is unlikely that the negative findings
in this study are a result of the data being analysed
using the scalp-derived method.
In summary, acute enhancement of serotonergic or
noradrenergic neurotransmission using citalopram and
reboxetine respectively had no effects on the LDAEP.
These findings together with previous findings in the
literature suggest that the LDAEP is a poor pharma-
codynamic marker of the serotonin and noradrenergic
systems.
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